Literature DB >> 19306260

Interval approach to assessing antitumor activity for tumor xenograft studies.

Jianrong Wu1, Peter J Houghton.   

Abstract

In preclinical cancer drug screening tumor xenograft experiments, the tumor growth inhibition ratio (T/C) is commonly used to assess the antitumor activity of the agents. Unfortunately, this measurement can discard useful data and result in a high false-negative rate. Furthermore, the degree of antitumor activity based on the T/C ratio is assessed on the basis of an arbitrary cutoff point that does not reflect variations in different tumor lines. To overcome these drawbacks, we propose an adjusted area-under-the-curve (aAUC) ratio to quantify tumor growth inhibition. A nonparametric bootstrap t-interval of the aAUC ratio is also proposed for assessing the significance of the antitumor activity of the agents. The proposed method is then applied to a real tumor xenograft study. (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19306260      PMCID: PMC2964842          DOI: 10.1002/pst.369

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  6 in total

1.  Comparison of antitumor activities in tumor xenograft treatment.

Authors:  Hua Liang
Journal:  Contemp Clin Trials       Date:  2006-05-17       Impact factor: 2.226

2.  The pediatric preclinical testing program: description of models and early testing results.

Authors:  Peter J Houghton; Christopher L Morton; Chandra Tucker; Debbie Payne; Edward Favours; Claire Cole; Richard Gorlick; E Anders Kolb; Wendong Zhang; Richard Lock; Hernan Carol; Mimi Tajbakhsh; C Patrick Reynolds; John M Maris; Joshua Courtright; Stephen T Keir; Henry S Friedman; Charles Stopford; Joseph Zeidner; Jianrong Wu; Tiebin Liu; Catherine A Billups; Javed Khan; Sherry Ansher; Jian Zhang; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2007-12       Impact factor: 3.167

3.  Modeling antitumor activity in xenograft tumor treatment.

Authors:  Hua Liang
Journal:  Biom J       Date:  2005-06       Impact factor: 2.207

4.  Discovery and preclinical antitumor efficacy evaluations of LY32262 and LY33169.

Authors:  Thomas H Corbett; Kathryn White; Lisa Polin; Juiwanna Kushner; Jennifer Paluch; Chuan Shih; Cora Sue Grossman
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

5.  Small-sample inference for incomplete longitudinal data with truncation and censoring in tumor xenograft models.

Authors:  Ming Tan; Hong-Bin Fang; Guo-Liang Tian; Peter J Houghton
Journal:  Biometrics       Date:  2002-09       Impact factor: 2.571

6.  Modeling antitumor activity by using a non-linear mixed-effects model.

Authors:  Hua Liang; Naijun Sha
Journal:  Math Biosci       Date:  2004-05       Impact factor: 2.144

  6 in total
  9 in total

1.  Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer.

Authors:  Tulasigeri M Totiger; Supriya Srinivasan; Venkatakrishna R Jala; Purushottam Lamichhane; Austin R Dosch; Alexander A Gaidarski; Chandrashekhar Joshi; Shobith Rangappa; Jason Castellanos; Praveen Kumar Vemula; Xi Chen; Deukwoo Kwon; Nilesh Kashikar; Michael VanSaun; Nipun B Merchant; Nagaraj S Nagathihalli
Journal:  Mol Cancer Ther       Date:  2018-11-07       Impact factor: 6.261

2.  Combining censored and uncensored data in a U-statistic: design and sample size implications for cell therapy research.

Authors:  Lemuel A Moyé; Dejian Lai; Kaiyan Jing; Mary Sarah Baraniuk; Minjung Kwak; Marc S Penn; Colon O Wu
Journal:  Int J Biostat       Date:  2011-07-22       Impact factor: 0.968

3.  Exploiting Dependence of Castration-Resistant Prostate Cancer on the Arginine Vasopressin Signaling Axis by Repurposing Vaptans.

Authors:  Laine M Heidman; Nahuel Peinetti; Valeria A Copello; Kerry L Burnstein
Journal:  Mol Cancer Res       Date:  2022-08-05       Impact factor: 6.333

4.  Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer.

Authors:  Austin R Dosch; Xizi Dai; Michelle L Reyzer; Siddharth Mehra; Supriya Srinivasan; Brent A Willobee; Deukwoo Kwon; Nilesh Kashikar; Richard Caprioli; Nipun B Merchant; Nagaraj S Nagathihalli
Journal:  Mol Cancer Res       Date:  2020-01-16       Impact factor: 5.852

Review 5.  Growth rate analysis and efficient experimental design for tumor xenograft studies.

Authors:  Gregory Hather; Ray Liu; Syamala Bandi; Jerome Mettetal; Mark Manfredi; Wen-Chyi Shyu; Jill Donelan; Arijit Chakravarty
Journal:  Cancer Inform       Date:  2014-12-09

6.  In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer.

Authors:  Marta Michalska; Susanne Schultze-Seemann; Lioudmila Bogatyreva; Dieter Hauschke; Ulrich Wetterauer; Philipp Wolf
Journal:  Oncotarget       Date:  2016-04-19

7.  Thioredoxin-1 protects against androgen receptor-induced redox vulnerability in castration-resistant prostate cancer.

Authors:  Govindi J Samaranayake; Clara I Troccoli; Mai Huynh; Rolando D Z Lyles; Karen Kage; Andrew Win; Vishalakshi Lakshmanan; Deukwoo Kwon; Yuguang Ban; Steven Xi Chen; Enrique Rodriguez Zarco; Merce Jorda; Kerry L Burnstein; Priyamvada Rai
Journal:  Nat Commun       Date:  2017-10-31       Impact factor: 14.919

8.  Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.

Authors:  Richard J Jones; Ram K Singh; Fazal Shirazi; Jie Wan; Hua Wang; Xiaobin Wang; Min Jin Ha; Muhamed Baljevic; Isere Kuiatse; Richard E Davis; Robert Z Orlowski
Journal:  Front Immunol       Date:  2020-08-13       Impact factor: 7.561

9.  The kinesin KIF20A promotes progression to castration-resistant prostate cancer through autocrine activation of the androgen receptor.

Authors:  Valeria A Copello; Kerry L Burnstein
Journal:  Oncogene       Date:  2022-04-13       Impact factor: 8.756

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.